American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.
Erlich
Rebecca
R
Thomson Scientific, Middlesex House, London, UK. rebecca.erlich@thomson.com
D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D018819:Dipeptidyl Peptidase 4 / Q000502:physiology*; D005934:Glucagon / Q000378:metabolism; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007515:Islets of Langerhans / Q000187:drug effects; D009570:Nitriles; D010446:Peptide Fragments / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D011498:Protein Precursors / Q000378:metabolism; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077597:Vildagliptin; D014970:Xanthines / Q000494:pharmacology
D009570:Nitriles; D010446:Peptide Fragments; D011480:Protease Inhibitors; D011498:Protein Precursors; D011719:Pyrazines; D011759:Pyrrolidines; D014230:Triazoles; D014970:Xanthines; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D018819:Dipeptidyl Peptidase 4; D000077597:Vildagliptin; D000218:Adamantane; D000068900:Sitagliptin Phosphate